Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage
NCT00198510 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to determine if intravitreal injection of Vitrase (ovine hyaluronidase) clears vitreous hemorrhage
Conditions Studied
Interventions
- DRUG Vitrase
Study Locations (20)
California
- Retina Vitreous Associates Medical Group — Beverly Hills
- Maria E. Castillejos, MD — Chula Vista
- Natural Vision — Fresno
- Eye Medical Center of Fresno — Fresno
- Jerry Sebag, MD — Huntington Beach
- University of California, Irvine — Irvine
- California VitreRetinal Center — Menlo Park
- Southern California Desert Retina Consultants — Palm Springs
- Retinal Consultants — Sacramento
- H. Richard McDonald, MD — San Francisco
- Santa Clara Valley Medical Centre — San Jose
- Robert L. Avery, MD — Santa Barbara
- Olive View/UCLA Medical Center — Sylmar
Colorado
- Retina Consultants of Southern Colorado — Colorado Springs
- University of Colorado Health Sciences Center — Denver
Connecticut
- Danbury Eye Physicians & Surgeons — Danbury
- New England Retina Associates — Hamden
Florida
- Florida Eye Clinic — Altamonte Springs
- Eye Centers of Florida — Fort Myers
Arizona
- Retina Centers, PC — Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 1998-11 |
| Est. Completion | 2003-03 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00198510
The ClinicalTrials.gov registry entry for NCT00198510 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 78 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Diabetic Retinopathy appearing as the primary indexed condition, and to 1 intervention — of which Vitrase is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00198510 reports 20 study locations spanning 5 distinct geographic areas — top geographies include California, Colorado, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00198510 about?
NCT00198510 is a clinical study titled "Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage". The purpose of this study is to determine if intravitreal injection of Vitrase (ovine hyaluronidase) clears vitreous hemorrhage
What is the current status of trial NCT00198510?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 750 participants. The study started on 1998-11. Estimated completion is 2003-03.
What conditions does trial NCT00198510 study?
This clinical trial studies the following conditions: Diabetic Retinopathy, Vitreous Hemorrhage. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00198510?
The interventions under investigation include: Vitrase (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00198510?
This trial is sponsored by Bausch & Lomb Incorporated, which has 78 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00198510 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.